167 related articles for article (PubMed ID: 38153903)
21. Immune checkpoint CD161/LLT1-associated immunological landscape and diagnostic value in oral squamous cell carcinoma.
Hu X; Dong Y; Xie S; Song Y; Yu C; He Y; Wang Z; Hu Q; Ni Y; Ding L
J Pathol Clin Res; 2024 Mar; 10(2):e353. PubMed ID: 38502058
[TBL] [Abstract][Full Text] [Related]
22. Percentages of CD4+CD161+ and CD4-CD8-CD161+ T cells in the synovial fluid are correlated with disease activity in rheumatoid arthritis.
Miao J; Zhang K; Qiu F; Li T; Lv M; Guo N; Han Q; Zhu P
Mediators Inflamm; 2015; 2015():563713. PubMed ID: 25960619
[TBL] [Abstract][Full Text] [Related]
23. Low levels of peripheral CD161++CD8+ mucosal associated invariant T (MAIT) cells are found in HIV and HIV/TB co-infection.
Wong EB; Akilimali NA; Govender P; Sullivan ZA; Cosgrove C; Pillay M; Lewinsohn DM; Bishai WR; Walker BD; Ndung'u T; Klenerman P; Kasprowicz VO
PLoS One; 2013; 8(12):e83474. PubMed ID: 24391773
[TBL] [Abstract][Full Text] [Related]
24. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies.
Zheng Z; Takahashi M; Aoki S; Toba K; Liu A; Osman Y; Takahashi H; Tsukada N; Suzuki N; Nikkuni K; Furukawa T; Koike T; Aizawa Y
J Exp Clin Cancer Res; 1998 Sep; 17(3):251-8. PubMed ID: 9894758
[TBL] [Abstract][Full Text] [Related]
25. CD1d-independent developmental acquisition of prompt IL-4 gene inducibility in thymus CD161(NK1)-CD44lowCD4+CD8- T cells is associated with complementarity determining region 3-diverse and biased Vbeta2/Vbeta7/Vbeta8/Valpha3.2 T cell receptor usage.
Chen YT; Kung JT
J Immunol; 2005 Nov; 175(10):6537-50. PubMed ID: 16272308
[TBL] [Abstract][Full Text] [Related]
26. CD161 (NKR-P1A) costimulation of CD1d-dependent activation of human T cells expressing invariant V alpha 24 J alpha Q T cell receptor alpha chains.
Exley M; Porcelli S; Furman M; Garcia J; Balk S
J Exp Med; 1998 Sep; 188(5):867-76. PubMed ID: 9730888
[TBL] [Abstract][Full Text] [Related]
27. Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome.
Braud VM; Biton J; Becht E; Knockaert S; Mansuet-Lupo A; Cosson E; Damotte D; Alifano M; Validire P; Anjuère F; Cremer I; Girard N; Gossot D; Seguin-Givelet A; Dieu-Nosjean MC; Germain C
Oncoimmunology; 2018; 7(5):e1423184. PubMed ID: 29721382
[TBL] [Abstract][Full Text] [Related]
28. CD161(int)CD8+ T cells: a novel population of highly functional, memory CD8+ T cells enriched within the gut.
Fergusson JR; Hühn MH; Swadling L; Walker LJ; Kurioka A; Llibre A; Bertoletti A; Holländer G; Newell EW; Davis MM; Sverremark-Ekström E; Powrie F; Capone S; Folgori A; Barnes E; Willberg CB; Ussher JE; Klenerman P
Mucosal Immunol; 2016 Mar; 9(2):401-13. PubMed ID: 26220166
[TBL] [Abstract][Full Text] [Related]
29. Expression of CD161 (NKR-P1A) defines subsets of human CD4 and CD8 T cells with different functional activities.
Takahashi T; Dejbakhsh-Jones S; Strober S
J Immunol; 2006 Jan; 176(1):211-6. PubMed ID: 16365412
[TBL] [Abstract][Full Text] [Related]
30. CD4+CD161+ T lymphocytes infiltrate Crohn's disease-associated perianal fistulas and are reduced by anti-TNF-α local therapy.
Maggi L; Capone M; Giudici F; Santarlasci V; Querci V; Liotta F; Ficari F; Maggi E; Tonelli F; Annunziato F; Cosmi L
Int Arch Allergy Immunol; 2013; 161(1):81-6. PubMed ID: 23257766
[TBL] [Abstract][Full Text] [Related]
31. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies.
Khubchandani S; Czuczman MS; Hernandez-Ilizaliturri FJ
Curr Opin Investig Drugs; 2009 Jun; 10(6):579-87. PubMed ID: 19513947
[TBL] [Abstract][Full Text] [Related]
32. CD161 is a marker of all human IL-17-producing T-cell subsets and is induced by RORC.
Maggi L; Santarlasci V; Capone M; Peired A; Frosali F; Crome SQ; Querci V; Fambrini M; Liotta F; Levings MK; Maggi E; Cosmi L; Romagnani S; Annunziato F
Eur J Immunol; 2010 Aug; 40(8):2174-81. PubMed ID: 20486123
[TBL] [Abstract][Full Text] [Related]
33. Decreased levels of circulating IL17-producing CD161+CCR6+ T cells are associated with graft-versus-host disease after allogeneic stem cell transplantation.
van der Waart AB; van der Velden WJ; van Halteren AG; Leenders MJ; Feuth T; Blijlevens NM; van der Voort R; Dolstra H
PLoS One; 2012; 7(12):e50896. PubMed ID: 23226545
[TBL] [Abstract][Full Text] [Related]
34. Enhancing Natural Killer and CD8
Ravindranath MH; Filippone EJ; Devarajan A; Asgharzadeh S
Monoclon Antib Immunodiagn Immunother; 2019 Apr; 38(2):38-59. PubMed ID: 31009335
[TBL] [Abstract][Full Text] [Related]
35. Increased Non-MAIT CD161
Liu Y; Wang W; Zhu P; Cheng X; Wu M; Zhang H; Chen Y; Chen Y; Liang Z; Wu X; Weng X
Cell Mol Gastroenterol Hepatol; 2023; 15(5):1181-1198. PubMed ID: 36787843
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of CD161+CD4+ T cells in the development of chronic antibody-mediated rejection in kidney transplant recipients.
Kim KW; Kim BM; Doh KC; Kim CD; Jeong KH; Lee SH; Yang CW; Chung BH
PLoS One; 2018; 13(7):e0200631. PubMed ID: 30011312
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of pre-transplant circulating CD3
Kim TW; Lee SE; Lim JY; Ryu DB; Jeon YW; Yoon JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Min CK
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27910184
[TBL] [Abstract][Full Text] [Related]
38. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
39. CD4+,CD28- T cells in rheumatoid arthritis patients combine features of the innate and adaptive immune systems.
Warrington KJ; Takemura S; Goronzy JJ; Weyand CM
Arthritis Rheum; 2001 Jan; 44(1):13-20. PubMed ID: 11212151
[TBL] [Abstract][Full Text] [Related]
40. Loss of Circulating CD8+ CD161
Acquaviva M; Bassani C; Sarno N; Dalla Costa G; Romeo M; Sangalli F; Colombo B; Moiola L; Martinelli V; Comi G; Farina C
Front Immunol; 2019; 10():1922. PubMed ID: 31474991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
